Research

model of DNA double helix

New type of trial shows promise for several cancers

Anti-cancer drugs are typically tested on one type of cancer at a time. But an international consortium of cancer investigators, including Vanderbilt-Ingram Cancer Center (VICC) researchers, simultaneously tested an existing therapy in patients with several different forms of cancer that all exhibit the same tumor gene mutation.

Macara lands award to explore cancer cell behavior

Vanderbilt’s Ian Macara, Ph.D., has won an Outstanding Investigator Award from the National Cancer Institute (NCI) — nearly $6.6 million over seven years — to support the “unusual potential” of his research, which seeks to understand and predict cancer cell “behavior.”

VUMC study shifts thinking on how bone fractures heal

New findings show that fibrin, a protein that was thought to play a key role in fracture healing, is not required, shifting understanding of how fractures heal.

concept illustration of knee with pain radiating from it

New targeted therapy shows promise for rare joint tumor

Vanderbilt-Ingram Cancer Center (VICC) investigators and colleagues at several major medical centers have been testing a new targeted therapy that is showing promise for the treatment of a rare tumor that forms in and around joint cavities.

Illustration of human intestinal tract

Study sheds light on human gut’s ‘pacemaker’ cells

The gut has its own built-in pacemakers, populations of specialized cells that control smooth muscle contraction in the stomach, small intestine and colon.

Worldwide Cancer Research lauds Macara’s contributions

Ian Macara, Ph.D., professor and chair of the Department of Cell and Developmental Biology, recently returned from Scotland, where he received this year’s Colin Thomson Memorial Medal for his contributions to cancer research.

1 115 116 117 118 119 136